Research Article
No access
Published Online: 22 December 2010

Effectiveness of Sitagliptin in Asian Indian Patients with Type 2 Diabetes—An Indian Tertiary Diabetes Care Center Experience

Publication: Diabetes Technology & Therapeutics
Volume 13, Issue Number 1

Abstract

Background: This study reports on the effectiveness of sitagliptin in Asian Indian type 2 diabetes patients seen at a tertiary diabetes care center who had inadequate glycemic control with oral hypoglycemic agents either alone or in combination, compared to a group of patients who received insulin glargine.
Patients and Methods: Patients with type 2 diabetes mellitus (n = 2,817) whose glycemia was not controlled adequately (glycated hemoglobin >6.5%) with oral hypoglycemic agents (either alone or in combination) received oral sitagliptin 100 mg once daily in addition to existing therapy for a period of 24 weeks. Patients who received insulin glargine as add-on therapy (n = 2,743) served as the reference group. Data analysis included glycated hemoglobin, fasting plasma glucose, lipid profile, body weight, and the occurrence of hypoglycemia.
Results: Significant reductions in glycated hemoglobin and fasting plasma glucose values were noted after 24 weeks of additional sitagliptin therapy that were comparable to those with insulin glargine. While sitagliptin addition resulted in a small weight loss (0.3 kg), insulin glargine addition resulted in a weight gain (0.7 kg). The overall incidence of adverse experiences was low and generally mild in both groups.
Conclusions: In a large group of Asian Indian type 2 diabetes patients seen at a tertiary diabetes center in whom glycemia was not controlled adequately by oral hypoglycemic agents (either alone or in combination), addition of sitagliptin helped to achieve glycemic control to a similar extent as insulin glargine but with a marginal weight advantage.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Unwin NWhiting DGan DJacqmain OGhyoot GIDF Diabetes Atlas4thBrusselsInternational Diabetes Federation200911-13. 1. Unwin N, Whiting D, Gan D, Jacqmain O, Ghyoot G, eds. IDF Diabetes Atlas, 4th ed. Brussels: International Diabetes Federation, 2009:11–13.
2.
Mohan VVenkatraman JVPradeepa R. Epidemiology of cardiovascular disease in type 2 diabetes: the Indian scenarioJ Diabetes Sci Technol20104158-170. 2. Mohan V, Venkatraman JV, Pradeepa R: Epidemiology of cardiovascular disease in type 2 diabetes: the Indian scenario. J Diabetes Sci Technol 2010;4:158–170.
3.
Shaw JESicree RAZimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030Diabetes Res Clin Pract2010874-14. 3. Shaw JE, Sicree RA, Zimmet PZ: Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010;87:4–14.
4.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) GroupLancet1998352837-853. 4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837–853.
5.
Gaede PVedel PParving HHPedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised studyLancet1999353617-622. 5. Gaede P, Vedel P, Parving HH, Pedersen O: Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999;353:617–622.
6.
Narayan KMGregg EWEngelgau MMMoore BThompson TJWilliamson DFVinicor F. Translation research for chronic disease: the case of diabetesDiabetes Care2000231794-1798. 6. Narayan KM, Gregg EW, Engelgau MM, Moore B, Thompson TJ, Williamson DF, Vinicor F: Translation research for chronic disease: the case of diabetes. Diabetes Care 2000;23:1794–1798.
7.
Glasgow RENutting PAKing DKNelson CCCutter GGaglio BRahm AKWhitesides HAmthauer H. A practical randomized trial to improve diabetes careJ Gen Intern Med2004191167-1174. 7. Glasgow RE, Nutting PA, King DK, Nelson CC, Cutter G, Gaglio B, Rahm AK, Whitesides H, Amthauer H: A practical randomized trial to improve diabetes care. J Gen Intern Med 2004;19:1167–1174.
8.
Kulasa KMHenry RR. Pharmacotherapy of hyperglycemiaExpert Opin Pharmacother2009102415-2432. 8. Kulasa KM, Henry RR: Pharmacotherapy of hyperglycemia. Expert Opin Pharmacother 2009;10:2415–2432.
9.
Garg SK. The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes—a comprehensive reviewDiabetes Technol Ther20101211-24. 9. Garg SK: The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes—a comprehensive review. Diabetes Technol Ther 2010;12:11–24.
10.
Aschner PKipnes MSLunceford JKSanchez MMickel CWilliams-Herman DESitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetesDiabetes Care2006292632-2637. 10. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE; Sitagliptin Study 021 Group: Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632–2637.
11.
Scott RWu MSanchez MStein P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetesInt J Clin Pract200761171-180. 11. Scott R, Wu M, Sanchez M, Stein P: Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007;61:171–180.
12.
Florentin MLiberopoulos ENMikhailidis DPElisaf MS. Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetesExpert Opin Pharmacother200891705-1720. 12. Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf MS: Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes. Expert Opin Pharmacother 2008;9:1705–1720.
13.
Nonaka KKakikawa TSato AOkuyama KFujimoto GKato NSuzuki HHirayama YAhmed TDavies MJStein PP. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetesDiabetes Res Clin Pract200879291-298. 13. Nonaka K, Kakikawa T, Sato A, Okuyama K, Fujimoto G, Kato N, Suzuki H, Hirayama Y, Ahmed T, Davies MJ, Stein PP: Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008;79:291–298.
14.
Mohan VYang WSon HYXu LNoble LLangdon RBAmatruda JMStein PPKaufman KD. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and KoreaDiabetes Res Clin Pract200983106-116. 14. Mohan V, Yang W, Son HY, Xu L, Noble L, Langdon RB, Amatruda JM, Stein PP, Kaufman KD: Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. Diabetes Res Clin Pract 2009;83:106–116.
15.
Scott RLoeys TDavies MJEngel SSSitagliptin Study 801 Group. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetesDiabetes Obes Metab200810959-969. 15. Scott R, Loeys T, Davies MJ, Engel SS; Sitagliptin Study 801 Group: Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008;10:959–969.
16.
Williams-Herman DJohnson JTeng RLuo EDavies MJKaufman KDGoldstein BJAmatruda JM. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week studyCurr Med Res Opin200925569-583. 16. Williams-Herman D, Johnson J, Teng R, Luo E, Davies MJ, Kaufman KD, Goldstein BJ, Amatruda JM: Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Curr Med Res Opin 2009;25:569–583.
17.
Rosenstock JBrazg RAndryuk PJLu KStein PSitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group studyClin Ther2006281556-1568. 17. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P; Sitagliptin Study 019 Group: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006;28:1556–1568.
18.
Hermansen KKipnes MLuo EFanurik DKhatami HStein PSitagliptin Study 035 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metforminDiabetes Obes Metab20079733-745. 18. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P; Sitagliptin Study 035 Group: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007;9:733–745.
19.
Luce BRKramer JMGoodman SNConnor JTTunis SWhicher DSchwartz JS. Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational changeAnn Intern Med2009151206-209. 19. Luce BR, Kramer JM, Goodman SN, Connor JT, Tunis S, Whicher D, Schwartz JS: Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change. Ann Intern Med 2009;151:206–209.
20.
Riddle MC. Timely initiation of basal insulinAm J Med2004116Suppl 3A3S-9S. 20. Riddle MC: Timely initiation of basal insulin. Am J Med 2004;116(Suppl 3A):3S–9S.
21.
Deepa MFarooq SDeepa RManjula DMohan V. Prevalence and significance of generalized and central body obesity in an urban Asian Indian population in Chennai, India (CURES: 47)Eur J Clin Nutr200963259-267. 21. Deepa M, Farooq S, Deepa R, Manjula D, Mohan V: Prevalence and significance of generalized and central body obesity in an urban Asian Indian population in Chennai, India (CURES: 47). Eur J Clin Nutr 2009;63:259–267.
22.
Friedewald WTLevy RIFredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifugeClin Chem197218499-502. 22. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502.
23.
American Diabetes Association. Standards of medical care in diabetes—2010Diabetes Care201033Suppl 1S11-S61. 23. American Diabetes Association: Standards of medical care in diabetes—2010. Diabetes Care 2010;33(Suppl 1):S11–S61.
24.
Ramachandran ASnehalatha CVijay V. Low risk threshold for acquired diabetogenic factors in Asian IndiansDiabetes Res Clin Pract200465189-195. 24. Ramachandran A, Snehalatha C, Vijay V: Low risk threshold for acquired diabetogenic factors in Asian Indians. Diabetes Res Clin Pract 2004;65:189–195.
25.
Ramachandran ASnehalatha CMary SMukesh BBhaskar ADVijay VIndian Diabetes Prevention Programme (IDPP). The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1)Diabetologia200649289-297. 25. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V; Indian Diabetes Prevention Programme (IDPP): The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006;49:289–297.
26.
Knowler WCBarrett-Connor EFowler SEHamman RFLachin JMWalker EANathan DMDiabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metforminN Engl J Med2002346393-403. 26. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403.
27.
DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial InvestigatorsGerstein HCYusuf SBosch JPogue JSheridan PDinccag NHanefeld MHoogwerf BLaakso MMohan VShaw JZinman BHolman RR. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trialLancet20063681096-1105. 27. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096–1105.
28.
Ramachandran ASnehalatha CMary SSelvam SKumar CKSeeli ACShetty AS. Pioglitazone does not enhance the effectiveness of lifestyle modification in preventing conversion of impaired glucose tolerance to diabetes in Asian Indians: results of the Indian Diabetes Prevention Programme-2 (IDPP-2)Diabetologia2009521019-1026. 28. Ramachandran A, Snehalatha C, Mary S, Selvam S, Kumar CK, Seeli AC, Shetty AS: Pioglitazone does not enhance the effectiveness of lifestyle modification in preventing conversion of impaired glucose tolerance to diabetes in Asian Indians: results of the Indian Diabetes Prevention Programme-2 (IDPP-2). Diabetologia 2009;52:1019–1026.
29.
Hollander PAKushner P. Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitorsPostgrad Med201012271-80. 29. Hollander PA, Kushner P: Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors. Postgrad Med 2010;122:71–80.
30.
Charbonnel BKarasik ALiu JWu MMeininger GSitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin aloneDiabetes Care2006292638-2643. 30. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G; Sitagliptin Study 020 Group: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29:2638–2643.
31.
Scheen AJVan Gaal LF. Sugar: results of a Belgian observational study on the use of sitagliptin in patients with type 2 diabetesRev Med Liege201065127-132. 31. Scheen AJ, Van Gaal LF: Sugar: results of a Belgian observational study on the use of sitagliptin in patients with type 2 diabetes. Rev Med Liege 2010;65:127–132.
32.
Williams-Herman DJohnson JTeng RGolm GKaufman KDGoldstein BJAmatruda JM. Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetesDiabetes Obes Metab201012442-451. 32. Williams-Herman D, Johnson J, Teng R, Golm G, Kaufman KD, Goldstein BJ, Amatruda JM: Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:442–451.
33.
Seck TNauck MSheng DSunga SDavies MJStein PPKaufman KDAmatruda JMSitagliptin Study 024 Group. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year studyInt J Clin Pract201064562-576. 33. Seck T, Nauck M, Sheng D, Sunga S, Davies MJ, Stein PP, Kaufman KD, Amatruda JM; Sitagliptin Study 024 Group: Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract 2010;64:562–576.
34.
Riche DMEast HERiche KD. Impact of sitagliptin on markers of beta-cell function: a meta-analysisAm J Med Sci2009337321-328. 34. Riche DM, East HE, Riche KD: Impact of sitagliptin on markers of beta-cell function: a meta-analysis. Am J Med Sci 2009;337:321–328.
35.
Peters AL. Patient and treatment perspectives: revisiting the link between type 2 diabetes, weight gain, and cardiovascular riskCleve Clin J Med200976Suppl 5S20-S27. 35. Peters AL: Patient and treatment perspectives: revisiting the link between type 2 diabetes, weight gain, and cardiovascular risk. Cleve Clin J Med 2009;76(Suppl 5):S20–S27.
36.
Pi-Sunyer FX. The effects of pharmacologic agents for type 2 diabetes mellitus on body weightPostgrad Med20081205-17. 36. Pi-Sunyer FX: The effects of pharmacologic agents for type 2 diabetes mellitus on body weight. Postgrad Med 2008;120:5–17.
37.
Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetesDiabetologia200245937-948. 37. Cryer PE: Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia 2002;45:937–948.

Information & Authors

Information

Published In

cover image Diabetes Technology & Therapeutics
Diabetes Technology & Therapeutics
Volume 13Issue Number 1January 2011
Pages: 27 - 32
PubMed: 21175268

History

Published in print: January 2011
Published online: 22 December 2010

Permissions

Request permissions for this article.

Topics

Authors

Affiliations

Chidambarann Sudhakaran, M.D.
Dr. Mohan's Diabetes Specialities Centre & Madras Diabetes Research Foundation, WHO Collaborating Centre for Non-communicable Diseases and International Diabetes Federation Centre of Education, Gopalapuram, Chennai, India.
Utkal Kishore, MBBS, FDiab
Dr. Mohan's Diabetes Specialities Centre & Madras Diabetes Research Foundation, WHO Collaborating Centre for Non-communicable Diseases and International Diabetes Federation Centre of Education, Gopalapuram, Chennai, India.
Ranjit Mohan Anjana, M.D.
Dr. Mohan's Diabetes Specialities Centre & Madras Diabetes Research Foundation, WHO Collaborating Centre for Non-communicable Diseases and International Diabetes Federation Centre of Education, Gopalapuram, Chennai, India.
Ranjit Unnikrishnan, M.D.
Dr. Mohan's Diabetes Specialities Centre & Madras Diabetes Research Foundation, WHO Collaborating Centre for Non-communicable Diseases and International Diabetes Federation Centre of Education, Gopalapuram, Chennai, India.
Viswanathan Mohan, M.D., FRCP, Ph.D., D.Sc.
Dr. Mohan's Diabetes Specialities Centre & Madras Diabetes Research Foundation, WHO Collaborating Centre for Non-communicable Diseases and International Diabetes Federation Centre of Education, Gopalapuram, Chennai, India.

Notes

Address correspondence to:Viswanathan Mohan, M.D., FRCP, Ph.D., D.Sc.Chairman & Chief of DiabetologyMadras Diabetes Research Foundation & Dr. Mohan's Diabetes Specialities CentreWorld Health Organization Collaborating Centre for Non-Communicable DiseasesInternational Diabetes Federation Centre of Education4, Conran Smith RoadGopalapuram, Chennai, 600 086,India
E-mail: [email protected]Website: www.drmohansdiabetes.comwww.mdrf.in

Author Disclosure Statement

No financial support was received exclusively towards this study. V.M. and the Madras Diabetes Research Foundation have received research support from MSD Pharmaceuticals, the makers of sitagliptin, and from Sanofi-Aventis, the makers of glargine insulin.

Metrics & Citations

Metrics

Citations

Export citation

Select the format you want to export the citations of this publication.

View Options

Get Access

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.

Society Access

If you are a member of a society that has access to this content please log in via your society website and then return to this publication.

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

View options

PDF/EPUB

View PDF/ePub

Full Text

View Full Text

Media

Figures

Other

Tables

Share

Share

Copy the content Link

Share on social media

Back to Top